rare disease trials China – Clinical Research Made Simple

Rare Disease Trials in China: Regulatory Pathways

digi — Thu, 09 Oct 2025 12:11:00 +0000

Rare Disease Trials in China: Regulatory Pathways

Regulatory Pathways for Rare Disease Clinical Trials in China

Introduction

Rare diseases affect an estimated 20 million people in China, yet historically these patients had limited access to innovative therapies. Clinical trials for rare diseases face unique challenges, including small patient populations, recruitment barriers, and limited disease registries. In recent years, the National Medical Products Administration (NMPA) has introduced regulatory pathways and incentives to encourage rare disease research, harmonizing with global best practices. China’s policy framework now includes expedited approvals, rare disease designation, and acceptance of multinational trial data. This article examines the regulatory pathways for rare disease trials in China, covering ethics, patient recruitment, global integration, and strategic considerations for sponsors.

Background and Regulatory Framework

Defining Rare Diseases in China

Unlike the U.S. Orphan Drug Act, China does not have a single statutory definition of rare diseases. Instead, the National Health Commission (NHC) publishes a “Rare Disease Catalog” that lists diseases qualifying for special regulatory support. The first catalog, published in 2018, included 121 diseases.

NMPA Rare Disease Pathways

The NMPA provides expedited review for drugs targeting catalog-listed rare diseases. Sponsors may apply for Breakthrough Therapy, Conditional Approval, or Priority Review status. These pathways shorten timelines and encourage investment in rare disease R&D.

Case Example: Spinal Muscular Atrophy Therapy

In 2019, a gene therapy for spinal muscular atrophy received conditional approval in China based on limited clinical data and strong unmet medical need. This case demonstrated the NMPA’s willingness to adopt flexible pathways for rare diseases.

Core Clinical Trial Insights

Patient Recruitment Challenges

Recruitment is constrained by small patient populations, lack of registries, and geographic dispersion. Sponsors often partner with patient advocacy groups and specialized Tier-1 hospitals to identify eligible patients. Decentralized trial models are increasingly explored to improve access for rural patients.

Ethical Considerations

Rare disease trials often involve pediatric populations or severely ill patients, requiring heightened ethical scrutiny. Informed consent must address risks, uncertainty, and long-term follow-up. Ethics committees review these protocols closely, sometimes extending timelines.

Role of Registries and Real-World Evidence (RWE)

China is expanding disease registries to support trial recruitment and long-term safety monitoring. RWE generated through registries and hospital networks is increasingly accepted by the NMPA to complement limited trial data, particularly in post-market settings.

Integration with Multinational Trials

The NMPA accepts multinational trial data if Chinese patients are included. This enables rare disease sponsors to leverage global development programs while meeting local regulatory requirements. Including 50–100 Chinese patients in a global trial can eliminate the need for separate bridging studies.

Compassionate Use and Expanded Access

China’s compassionate use programs allow patients with serious rare diseases to access investigational therapies before approval. While limited in scope, these programs demonstrate growing regulatory flexibility and patient-centeredness.

Pharmacovigilance and Long-Term Follow-Up

Rare disease therapies, especially gene and cell therapies, require intensive post-market safety monitoring. Sponsors must develop risk management plans (RMPs) with long-term follow-up protocols to satisfy NMPA expectations.

Best Practices & Preventive Measures

Sponsors should partner early with advocacy groups, establish collaborations with Tier-1 hospitals, and explore decentralized trial models for broader patient access. Regulatory engagement is critical to clarify expectations for trial design, patient numbers, and data acceptance. Building registries and integrating RWE strengthens submissions and accelerates approval.

Scientific & Regulatory Evidence

China’s rare disease policies align with ICH E6(R2) GCP, ICH E17 MRCT guidelines, and WHO principles. The Rare Disease Catalog and 2019 Drug Administration Law underpin China’s approach, while conditional approvals mirror FDA accelerated approval and EMA PRIME programs. These frameworks demonstrate convergence with global regulatory practices.

Special Considerations

Pediatric patients represent a large proportion of rare disease populations, requiring tailored protocols, dosing studies, and informed consent procedures. HGRAC approval is mandatory when genetic resources are involved, adding another compliance layer. Sponsors must balance speed with ethical rigor in designing rare disease trials.

When Sponsors Should Seek Regulatory Advice

Sponsors should consult the NMPA and HGRAC early in protocol development for rare disease trials. Regulatory advice clarifies expectations for patient numbers, trial designs, and genetic data use. Early consultation with ethics committees ensures protocols address pediatric and vulnerable populations appropriately.

Case Studies

Case Study 1: Pediatric Rare Disease Trial

A multinational sponsor conducted a pediatric rare disease trial at Tier-1 hospitals in Beijing and Shanghai. By partnering with patient advocacy groups and including 80 Chinese patients in the global trial, the sponsor avoided a separate bridging study and achieved NMPA approval within 12 months.

Case Study 2: Gene Therapy Conditional Approval

A domestic biotech company developed a gene therapy for a catalog-listed rare disease. With limited Phase II data but strong unmet need, the NMPA granted conditional approval, requiring post-market RWE studies. This case illustrated regulatory flexibility in balancing urgency with safety.

FAQs

1. What qualifies as a rare disease in China?

Diseases listed in the National Health Commission’s Rare Disease Catalog qualify for regulatory incentives and expedited pathways.

2. Does China have orphan drug legislation?

Not formally, but the Rare Disease Catalog and NMPA expedited pathways provide orphan drug-like benefits.

3. How does China support rare disease recruitment?

Through registries, advocacy partnerships, and inclusion of rare disease centers in Tier-1 hospitals, though recruitment remains challenging.

4. Can multinational trial data be used in China?

Yes, if Chinese patients are included. Adequate representation reduces the need for bridging studies.

5. What is the role of RWE in rare disease trials?

RWE complements limited trial data, supports post-market commitments, and is increasingly accepted by the NMPA.

6. What are the main regulatory pathways for rare diseases?

Breakthrough Therapy, Conditional Approval, and Priority Review are available for drugs targeting rare diseases in the catalog.

Conclusion & Call-to-Action

China’s regulatory pathways for rare disease trials have evolved rapidly, providing expedited approvals, data flexibility, and patient access programs. For sponsors, success requires early engagement with regulators, robust patient recruitment strategies, and collaboration with advocacy groups. Organizations planning rare disease trials in China must integrate NMPA requirements, HGRAC approvals, and global harmonization principles to accelerate development and deliver innovative therapies to patients in need.

How China’s HGRAC Affects Global Rare Disease Trials

digi — Fri, 03 Oct 2025 21:07:09 +0000

How China’s HGRAC Affects Global Rare Disease Trials

The Impact of HGRAC Rules on Rare Disease Clinical Trials in China

Introduction

Rare disease clinical trials often depend on global collaboration, with sponsors seeking diverse genetic data and patient cohorts across regions. In China, the Human Genetic Resources Administration of China (HGRAC) plays a pivotal regulatory role in governing the collection, use, and export of human genetic resources, including biospecimens and genetic data. For multinational sponsors, HGRAC approval is a critical prerequisite for conducting rare disease studies in China, particularly since these trials frequently involve small patient populations and cross-border data sharing. While these regulations are designed to protect national interests and patient rights, they can pose significant operational and compliance challenges. This article examines how HGRAC requirements shape global rare disease trials, the regulatory processes involved, and strategies for sponsors to navigate this complex landscape while ensuring patient access to innovative therapies.

Background and Regulatory Framework

Origins of HGRAC Oversight

HGRAC oversight began in the late 1990s as part of China’s efforts to safeguard national genetic resources. The regulations were codified under the “Regulations on the Administration of Human Genetic Resources” (1998) and have been updated multiple times, most recently in 2019. These rules mandate government approval for the collection, storage, and export of genetic materials and related data.

HGRAC and NMPA Coordination

While the NMPA oversees the clinical trial framework, HGRAC specifically regulates human genetic resources used in those trials. This dual oversight means sponsors must secure both NMPA and HGRAC approvals before initiating rare disease studies involving genetic data or samples.

Case Example: Delayed Approvals

Several multinational sponsors have reported trial delays due to lengthy HGRAC review timelines, particularly when applications involved cross-border data transfer. These experiences highlight the need for early planning and close regulatory engagement.

Core Clinical Trial Insights

Approval Requirements for Rare Disease Trials

Sponsors conducting rare disease trials must submit detailed HGRAC applications that describe the study purpose, genetic resources involved, sample management, and plans for data sharing. Joint ventures with Chinese institutions are often required, ensuring local participation and oversight. Without HGRAC approval, trials cannot lawfully proceed.

Export Restrictions on Genetic Materials

HGRAC prohibits the export of Chinese human genetic resources without prior authorization. For rare disease trials that rely on global genetic analyses, this can create significant hurdles. Sponsors must either establish local laboratories in China or partner with accredited Chinese research institutions to perform testing domestically.

Data Localization and Sharing

China’s data localization laws require that genetic data generated in China remain stored on domestic servers. While anonymized or aggregated data may sometimes be shared internationally, individual-level genetic data are subject to strict controls. This creates challenges for multinational data integration, particularly in rare diseases where sample sizes are small.

Impact on Multinational Trial Design

Because of HGRAC restrictions, sponsors often need to redesign trial protocols to accommodate local testing and data analysis. This can affect timelines, costs, and harmonization with global study arms. Sponsors must also navigate additional ethics committee reviews tied to genetic data handling.

Ethical Considerations for Rare Disease Patients

Rare disease patients in China often seek access to global investigational therapies. While HGRAC oversight ensures ethical safeguards, delays in approvals can inadvertently limit patient access. Balancing national interests with urgent medical needs remains a central tension in rare disease regulation.

Role of CROs and Local Partnerships

Local CROs and academic institutions are indispensable for navigating HGRAC processes. They provide insight into evolving policies, assist with documentation, and ensure compliance with domestic laboratory and data storage requirements. Strategic partnerships are often the key to timely trial initiation.

Best Practices & Preventive Measures

Sponsors should begin HGRAC application preparation at the earliest stages of protocol development. Establishing partnerships with accredited Chinese research institutions can reduce approval risks. Sponsors should also design trial data management systems that comply with localization laws, and ensure transparency with patients and ethics committees regarding data handling. Regular communication with regulators helps mitigate delays.

Scientific & Regulatory Evidence

HGRAC regulations are informed by international principles of data protection and sovereignty. Comparisons can be drawn with the EU’s General Data Protection Regulation (GDPR) and U.S. laws on genetic privacy. However, China’s emphasis on national ownership of genetic resources distinguishes its framework. ICH E6(R2) and WHO GCP guidelines provide complementary ethical standards for rare disease trials that intersect with HGRAC oversight.

Special Considerations

Rare disease trials face unique challenges in China due to limited patient registries and diagnostic infrastructure. HGRAC requirements can exacerbate delays in trial initiation, making it essential for sponsors to collaborate with patient advocacy organizations to identify eligible patients. Pediatric rare disease trials, in particular, demand careful ethical review and parental involvement in consent processes.

When Sponsors Should Seek Regulatory Advice

Sponsors should consult HGRAC during the earliest phases of study design, especially when genetic samples or data transfer are involved. Pre-submission meetings with both HGRAC and NMPA can clarify expectations and reduce review delays. Sponsors should also seek advice when considering multi-regional rare disease trials that include China, to ensure compliance with global and domestic requirements.

Case Studies

Case Study 1: Rare Disease Trial with Delayed Sample Export

A multinational rare disease study faced a six-month delay due to HGRAC’s restrictions on exporting patient samples for overseas genomic analysis. The sponsor responded by establishing a local laboratory partnership in Beijing, which allowed the trial to proceed without further delays while ensuring compliance with localization laws.

Case Study 2: Successful Joint Venture Model

Another rare disease sponsor partnered with a Chinese academic institution to form a joint venture for data management. This collaboration streamlined HGRAC approval and improved patient recruitment by leveraging the institution’s existing rare disease registry. The trial became a model for international-local collaboration under HGRAC oversight.

FAQs

1. What is HGRAC and why is it important?

HGRAC is the Human Genetic Resources Administration of China. It regulates the collection, use, and export of human genetic resources in clinical trials.

2. Do rare disease trials always need HGRAC approval?

Yes, if genetic samples or data are involved, HGRAC approval is mandatory in addition to NMPA authorization.

3. Can genetic data from China be shared internationally?

Only under strict conditions. Individual-level data cannot leave China without authorization, and most data must remain on domestic servers.

4. How long does HGRAC approval take?

Approval timelines vary but can take several months. Early preparation and local partnerships help mitigate delays.

5. Can sponsors export patient samples from China?

Not without HGRAC authorization. In most cases, testing must be conducted within China at accredited laboratories.

6. What strategies help sponsors comply with HGRAC?

Forming joint ventures with local institutions, designing compliant data management systems, and engaging HGRAC early in protocol design are best practices.

Conclusion & Call-to-Action

HGRAC regulations significantly shape how rare disease trials are designed and conducted in China. While these rules protect national interests and patient rights, they also create challenges for multinational sponsors seeking to integrate Chinese data into global studies. By planning early, building strong local partnerships, and aligning protocols with HGRAC requirements, sponsors can overcome barriers and ensure rare disease patients in China have timely access to innovative therapies. Organizations considering rare disease trials in China should consult regulatory experts to design compliant, patient-centered strategies that support both global and domestic research goals.